Volume : 10, Issue : 01, January – 2023



Authors :

Dr. Santosh Uttangi, J.S. Venkatesh, Sheril K S*, Shyno Sunny*, Sumanth S* and Anky T*

Abstract :

Fidaxomicin is a new macrocyclic antibiotic with a narrow spectrum. It inhibits bacterial RNA polymerase and kills C difficile while having little impact on normal intestinal flora. On January 10, 2011, the US FDA granted orphan drug designation to all formulations of Fidaxomicin for the treatment of C difficile infections in paediatric patients. Fidaxomicin is bactericidal against Clostridium difficile and has a long post-antibiotic effect. Despite the fact that this medication has an orphan designation for paediatrics, all available pharmacokinetic and pharmacodynamic data were from subjects over the age of 18.Fidaxomicin is a bactericidal antibiotic with a long post-antibiotic effect against Clostridium difficile. Despite the fact that this medication is designated as orphan for paediatrics, all available pharmacokinetic and pharmacodynamic data were from subjects over the age of 18. Fidaxomicin’s MIC90 against Clostridium difficile ranges from 0.0078-0.25 mcg/ml. Fidaxomicin has a poor absorption rate. Patients receiving fidaxomicin had the highest peak plasma concentration of 0.191 mcg/ml. Fidaxomicin faeces are extremely high after oral administration. In the 100, 200, and 400 mg/day groups, the average faecal concentrations in C difficile patients were 255.6 mcg/g, 441.7 mcg/g, and 1443.3 mcg/g, respectively. The average faecal concentration at 400 mg/day was 5700 times greater than the highest MIC90 of fidaxomicin against C difficile. Fidaxomicin 200 mg twice day and vancomycin 125 mg four times daily were contrasted for 10 days in a phase III clinical research. No patients under the age of 18 took part in the study, and only two patients were under 18. Fidaxomicin’s clinical cure rates were comparable to those of vancomycin. Patients in the fidaxomicin group saw fewer recurrences than those in the vancomycin group when they had non-North American Pulsed Field type 1 strains of the infection. Both treatments’ side effects were comparable. The majority of patients only had minor gastrointestinal problems. Vancomycin and metronidazole are both effective treatment alternatives to fidaxomicin, particularly for individuals who have C difficile infections that keep coming back. Systemic side effects are uncommon in patients, which increases compliance. The dose of fidaxomicin is expected to be 200 mg given orally twice a day for patients 16 years and older. Additional clinical trials in pediatric patients are needed before therapeutic recommendations can be made in this population.
KEYWORDS: Fidaxomicin; Pediatrics; Clostridium difficile; Phar-macokinetic, pharmacodynamics.

Cite This Article:

Please cite this article in press Santosh Uttangi et al, A Review On Fidaxomicin For The Treatment Of Clostridium Difficile Infection In Paediatrics., Indo Am. J. P. Sci, 2023; 10 (01).

Number of Downloads : 10


1. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346(5):334-339.
2. Fekety R. Guidelines for the diagnosis and management Of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92(5):739-750.
3. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320(4):204-210.
4. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther 2000;25(2):101-109.
5. Nylund CM, Goudie A, Garza JM, Fairbrother G, Cohen MB. Clostridium difficile Infection in Hospitalized Children in the United States. Arch Pediatr Adolesc Med 2011;165(5):451-457.
6. Gouliouris T, Brown NM, Aliyu SH. Prevention and Treatment of Clostridium difficile infection. Clin Med 2011;11(1):75-79.
7. Optimer Pharmaceuticlls, Inc. (2011). Fidaxomicin. Retrieved March 8, 2011 from http://www.optimerpharma.Com/pipeline.asp?pipeline=1.
8. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro Activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48(6):2280-2282.
9. Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers Following single and multiple oral doses. Antimicrob Agents Chemother 2008;52(4):1391-1395.
10. Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 2010;11(9):1569-1578.
11. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Investig Drugs 2008;17(4):547-553.
12. Citron DM, Babakhani F, Goldstein EJ, Nagaro K, Sambol S, Sears P, Shue YK, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT80) phase II study for C. Difficile infection. Anaerobe 2009;15(6):234-236.
13. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-431.
14. Optimer Pharmaceuticlls, Inc. (2011). Fidaxomicin. Retrieved April 12, 2011 from http://www.optimerpharma.Com/fidaxomicin.